Prostate cancer patients who receive permanent radiotherapy implants twice as likely to be free of cancer after five years
Barcelona, Spain: Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later.
Presenting these results at the 3rd ESTRO Forum in Barcelona, Spain, on Monday, Professor James Morris, from the Department of Radiation Oncology, Vancouver Cancer Centre, British Columbia Cancer Agency (BCCA), Vancouver, Canada, said that the ASCENDE-RT1 trial is the first and only existing trial comparing low-dose-rate prostate brachytherapy (LDR-PB) for the curative treatment of prostate cancer with any other method of radiation therapy delivery.
The trial enrolled 398 men with cancer that had not spread outside the prostate gland who were judged to be at high risk of treatment failure, based on standard tests for a number of features of the cancer. The patients initially received androgen deprivation therapy (ADT), aimed at reducing levels of the male hormones that stimulate prostate cancer cells to grow. After eight months of ADT, all patients received 46 Gy2 of external beam radiotherapy to the prostate and regional lymph nodes.
Following this, 198 men received LDR-PB in which tiny radioactive seeds were implanted in the prostate gland while under general or spinal anaesthesia. The other 200 patients were randomised to dose-escalated external beam radiation therapy (DE-EBRT) and received an additional 32 Gy of external beam radiation to achieve a total prostate dose of 78 Gy.
“At five years follow up, we saw a large advantage in progression-free survival in the LDR-PB group,” said Prof Morris. “Although, to date, overall survival and prostate cancer-specific survival do not appear to differ between the two groups, existing trends favour LDR-PB and an overall survival advantage is likely to emerge with longer follow-up.”
LDR-PB is an extremely cost-effective treatment, the researchers say, but it does require prolonged training and experience in order to produce consistent results, and this may limit more widespread adoption. An additional problem is that, in the trial, the LDR-PB patients experienced more urinary side effects that those who received DE-EBRT. In a separate presentation Prof Morris’s Clinical Research Fellow, Dr Sree Rodda, told the conference that the incidence of severe late urinary side effects was three times higher in patients who received LDR-PB than in those who had DE-EBRT.
“Many of these severe adverse effects were temporary and reversible, or could be ameliorated by procedures. Moreover, more than 80% of patients in the LDR-PB arm had few or no long term urinary side effects.” However, she said: “the long-term prevalence of severe urinary toxicity in the LDR-PB patients was 8% compared to just 2% for the DE-EBRT patients. An important challenge for the future will be the reduction of these adverse effects while maintaining the advantages of LDR-PB.”
At BCCA’s five cancer centres, LDR-PB boost is now regarded as the standard of care for unfavourable risk localised prostate cancer. “The ideal next step would be to undertake randomised comparisons of LDR-PB boost against its principal alternatives – temporary high-dose-rate brachytherapy implants (HDR-PB)3, stereotactic body radiation therapy using extreme hypofractionation4, and combined surgery and post-operative radiation therapy,” said Prof Morris.
“In the meantime, ASCENDE-RT has made an important contribution to the search for a more effective curative treatment for prostate cancer,” he concluded.
Professor Philip Poortmans, President of ESTRO, commented: “This study illustrates very nicely how the best results can be obtained by combining various treatment options instead of trying to get the most out of one single modality. Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field of applicability than simply in very localised and low risk tumours when combined with other techniques – in this case, androgen deprivation therapy and external bean radiation therapy.”
Morris: abstract no. OC-0485: “LDR Brachytherapy is Superior to 78 Gy of EBRT for Unfavourable Risk Prostate Cancer: The Results of a Randomized Trial”, Highest scoring 3rd ESTRO Forum abstracts session at 11.50 hrs (CEST) on Monday, 27 April, Main Auditorium.
Rodda: abstract no. PD-0047 GU and GI toxicity in ASCENDE-RT*: A Multicentre Randomized Trial of Dose-Escalated Radiation for Prostate Cancer, poster session.
1. Androgen Suppression Combined with Elective Nodal and Dose Escanodal and Dose Escalated Radiation Therapy.
2. A Gray, or Gy, is a measure of radiation dose, defined as the absorption of one joule of energy per kilogram of tissue.
3. A radiation treatment using temporary implants to deliver high-dose-rate brachytherapy.
4. A form of external beam radiation therapy that delivers a few very large fractions of radiation using new high precision technology.
5. The research was funded entirely by unrestricted educational grants to the BCCA from:
– Oncura Corporation (a subsidiary of GE Healthcare and the manufacturer of the radioactive seeds used in the trial).
– Sanofi-Aventis, Canada (the maker of the Suprefact and Eligard anti-androgen injections used in the trial).
The European Society for Radiotherapy and Oncology (ESTRO) 3rd Forum is attended by about 3000 delegates from more than 80 countries. It features new research results in clinical radiation oncology, radiobiology, physics, technology, and brachytherapy, presented by top doctors and scientists from all over the world.